Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non-phosphorylated and phosphorylated VEGFR2

Bioorganic & Medicinal Chemistry
2011.0

Abstract

A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylated VEGFR2 was slow and the half-life of the complex was longer than 4h. In contrast, dissociation of 20d from the phosphorylated enzyme was very fast (half-life <5min). A fluorescent tracer based displacement assay and surface plasmon resonance (SPR) analysis confirmed the slow dissociation of 20d from only non-phosphorylated VEGFR2. Thus, activity based and binding kinetic analyses both supported slow dissociation of 20d from only non-phosphorylated VEGFR2. Additionally SPR analysis revealed that association rates were rapid and nearly identical for these two phosphorylation forms of VEGFR2. From these results, the preferential effect of 20d on non-phosphorylated VEGFR2 is dominated by its slow dissociation from the enzyme and this characteristically long residence time may increase its potency in vivo. The present findings may assist in the design of novel type-II kinase inhibitors.

Knowledge Graph

Similar Paper

Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non-phosphorylated and phosphorylated VEGFR2
Bioorganic &amp; Medicinal Chemistry 2011.0
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors
European Journal of Medicinal Chemistry 2010.0
Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach
Bioorganic &amp; Medicinal Chemistry Letters 2013.0
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2
European Journal of Medicinal Chemistry 2015.0
Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors
European Journal of Medicinal Chemistry 2014.0
Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking
Bioorganic &amp; Medicinal Chemistry Letters 2019.0
Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization
ACS Medicinal Chemistry Letters 2015.0
Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors
Bioorganic &amp; Medicinal Chemistry 2016.0
Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: synthesis,in vitrobiological evaluation and molecular docking
MedChemComm 2018.0
Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors
Bioorganic &amp; Medicinal Chemistry 2015.0